This study is currently not recruiting participants.

Phase II Trial of Gemcitabine Cisplatin plus Ipilimumab as First-Line Treatment for Patients with Metastatic Urothelial Carcinoma

Investigating the Safety and Effectiveness of an Investigational Medication Used Alone or Together with Other Treatments

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this research study is to see the safety and effectiveness of Ipilimumab when given alone or when given in combination with Gemcitabine and cisplatin.

Detailed description of study

The purpose of this research study is to see the safety and effectiveness of Ipilimumab when given alone or when given in combination with Gemcitabine and cisplatin.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Metastatic Urothelial Carcinoma
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the safety and effectiveness of an investigational medication when given alone or in combination with other treatments. The investigational medication is being studied to understand how well it works and how safe it is when used by itself or together with other drugs.

Participants in this study will receive either the investigational medication alone or in combination with other treatments. The study will monitor their health and any effects of the treatment to gather information about the medication's safety and effectiveness.

  • Who can participate: Participants must meet specific age criteria and other key eligibility factors to be considered for this study.
  • Study details: Participants will be assigned to receive either the investigational medication by itself or together with other treatments. A placebo is not used in this study.
Updated on 19 Feb 2024. Study ID: 1110007307

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team